Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFN50 in Autoimmune Diseases
NCT07408336Phase 1Recruiting
- Sponsor
- AlphaNa Bioscience
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AFN50 in systemic lupus erythematosus (SLE), sponsored by AlphaNa Bioscience. Primary endpoint: Adverse events at 3 months. Started Feb 2026; status: recruiting.
02
Drugs
AFN50
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07408336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408336.